Alzamend Neuro (ALZN) vs Traws Pharma (TRAW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Traws Pharma is the larger company by market cap ($6.8 million vs $6.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALZN | TRAW |
|---|---|---|
| Share price | $1.34 | $0.4452 |
| Market cap | $6.47M | $6.84M |
| 1-day change | 0.00% | -7.31% |
| EPS (TTM) | $-2.33 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.68 | $3.27 |
| 52-week low | $0.84 | $0.43 |
| Distance from 52-week high | -50.00% | -86.39% |
| Analyst consensus | none | none |
| Avg. price target upside | +1840.30% | +124.62% |
| Average volume | 88.54K | 569.02K |
| Shares outstanding | 4.83M | 15.37M |
| Employees | 4 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Alzamend Neuro
ALZN stock →Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Traws Pharma
TRAW stock →Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
ALZN vs TRAW FAQ
Which is bigger, Alzamend Neuro or Traws Pharma?
Traws Pharma (TRAW) is larger, with a market capitalization of $6.84M compared with $6.47M for Alzamend Neuro (ALZN).
Are Alzamend Neuro and Traws Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.